Multitarget PPARγ agonists as innovative modulators of the metabolic syndrome

Eur J Med Chem. 2019 Jul 1:173:261-273. doi: 10.1016/j.ejmech.2019.04.030. Epub 2019 Apr 13.

Abstract

A multitarget pharmacologic approach could be advantageous for the therapy of metabolic multiple diseases, such as the metabolic syndrome, which is characterized by metabolic abnormalities associated with diabetes, obesity, hypertension, and increased cardiovascular risk. PPAR receptors play a critical role in metabolic disorders, affecting glucose and lipid metabolism. Drugs simultaneously targeting PPAR and other validated metabolic targets, represent a promising multitarget approach to combine antihyperglycemic, antihyperlipidemic, and antihypertensive effects. This review offers a survey of recently developed multitarget PPARγ agonists as antidiabetic and antihypertensive drugs.

Keywords: AT1 receptor; FFAR1; GK; Metabolic syndrome; Multitarget drugs; PPAR; PTP1B; SUR; sEH.

Publication types

  • Review

MeSH terms

  • Animals
  • Antihypertensive Agents / chemistry
  • Antihypertensive Agents / pharmacology*
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Dose-Response Relationship, Drug
  • Humans
  • Hypertension / drug therapy*
  • Hypoglycemic Agents / chemistry
  • Hypoglycemic Agents / pharmacology*
  • Metabolic Syndrome / drug therapy*
  • Molecular Structure
  • PPAR gamma / agonists*
  • Structure-Activity Relationship

Substances

  • Antihypertensive Agents
  • Hypoglycemic Agents
  • PPAR gamma